Glutaminase Inhibitors—Do They Have a Role in the Treatment of Metastatic Clear-Cell Renal Cell Carcinoma?
Mené sur 444 patients atteints d'un carcinome à cellules rénales de stade avancé, cet essai randomisé évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité de l'ajout du télaglénastat (un inhibiteur de la glutaminase) au cabozantinib après l'échec de 1 ou 2 lignes thérapeutiques
Compared with normal cells, tumor cells exhibit an increased dependency on the glutaminase-controlled conversion of glutamine to glutamate to provide energy for growth and survival, providing a rationale for glutaminase inhibition as part of anticancer therapy. Several cancer cell types, including prostate cancer, melanoma, non–small cell lung cancer, and renal cell carcinoma (RCC), are known to overexpress glutaminase. The safety and efficacy of the glutaminase inhibitor telaglenastat, usually in combination with anticancer drugs, have been assessed in several ongoing or completed clinical studies of these cancer types.
JAMA Oncology , commentaire, 2021